Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update

Manfred Kaufmann, Gabriel N. Hortobagyi, Ann Goldhirsch, Suzy Scholl, Andreas Makris, Pinuccia Valagussa, Jens Uwe Blohmer, Wolfgang Eiermann, Raimund Jackesz, Walter Jonat, Annette Lebeau, Sibylle Loibl, William Miller, Sigfried Seeber, Vladimir Semiglazov, Roy Smith, Rainer Souchon, Vered Stearns, Michael Untch, Gunter Von Minckwitz

Research output: Contribution to journalArticle

Abstract

Neoadjuvant (primary systemic) treatment is the standard treatment for locally advanced breast cancer and a standard option for primary operable disease. Because of new treatments and new understandings of breast cancer, however, recommendations published in 2003 regarding neoadjuvant treatment for operable disease required updating. Therefore, a second international panel of representatives of a number of breast cancer clinical research groups was convened in September 2004 to update these recommendations. As part of this effort, data published to date were reviewed critically and indications for neoadjuvant treatment were newly defined.

Original languageEnglish
Pages (from-to)1940-1949
Number of pages10
JournalJournal of Clinical Oncology
Volume24
Issue number12
DOIs
Publication statusPublished - Apr 20 2006

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kaufmann, M., Hortobagyi, G. N., Goldhirsch, A., Scholl, S., Makris, A., Valagussa, P., Blohmer, J. U., Eiermann, W., Jackesz, R., Jonat, W., Lebeau, A., Loibl, S., Miller, W., Seeber, S., Semiglazov, V., Smith, R., Souchon, R., Stearns, V., Untch, M., & Von Minckwitz, G. (2006). Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update. Journal of Clinical Oncology, 24(12), 1940-1949. https://doi.org/10.1200/JCO.2005.02.6187